Advertisement

Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2947 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Scenic Biotech–Netherlands (govt): credit, 202006– Innovation Credit €3.1m from RVO to advance QPCTL inhibitors 2020-06-23
GSK–Ideaya Biosciences: synthetic lethality, 202006– collab strategic partnership ww $100m upfront + milestones + royalties 2020-06-16
Ideaya Biosciences–GSK: investment, 202006 direct private placement $20m common stock purchase by GSK 2020-06-16
Ona Therapeutics–Optimum Strategic Communications: public relations, 202006 service existent by Optimum 2020-06-16
Bit Bio–ARCH Venture: investment, 202006 financing round Series A totalling $41.5m incl co-investor Arch Venture Partners 2020-06-13
Bit Bio–BY Capital: investment, 202006 financing round Series A totalling $41.5m incl co-investor BlueYard Capital 2020-06-13
Bit Bio–Foresite Capital: investment, 202006 financing round Series A totalling $41.5m incl co-investor Foresite Capital 2020-06-13
Bit Bio–Mission Group: public relations, 202006 service existent by April Six 2020-06-13
Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Bob Nelsen 2020-06-13
Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Jim Tananbaum 2020-06-13
Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Rick Klaunser 2020-06-13
Bit Bio–SEVERAL: investment, 202006 financing round Series A $41.5m led by Rick Klaunser + Bob Nelsen + Jim Tananbaum 2020-06-13
Valo Therapeutics–Scius Communications: public relations, 202006 supply service existent by Scius Communications 2020-06-08
Tropic Biosciences–SEVERAL: investment, 202006 financing round Series B $28.5m led by Temasek 2020-06-04
Tropic Biosciences–Temasek: investment, 202006 financing round Series B totalling $28.5m incl new + lead investor Temasek 2020-06-04
Base Genomics–SEVERAL: investment, 202006 seed financing round £9m ($11m) led by Oxford Sciences Innovation 2020-06-03
Base Genomics–Univ Oxford: investment, 202006 seed financing round totalling £9m incl lead investor Oxford Sciences Innovation 2020-06-03
Base Genomics–Zyme Communications: public relations, 202006 service existent by Zyme 2020-06-03
NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures 2020-06-03
Prilenia–Instinctif Partners: public relations, 202006 service existent by Instinctif 2020-06-03
Rigenerand–Image Box: public relations, 202005– supply service by Image Box PR 2020-05-29
Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital 2020-05-26
GSK–Samsung: biologicals contract manufacturing, 202005–2028 supply up to $231m of Benlysta + other biologics by Samsung Biologics 2020-05-21
HotSpot Therapeutics–GSK: investment, 202005 financing round Series B totalling $65m incl lead investor SR One 2020-05-21
HotSpot Therapeutics–SEVERAL: investment, 202005 financing round Series B $65m led by SR One 2020-05-21
Rentschler–Horizon Discovery: cell line development, 202005– license to CHOSource platform for cell line developm for difficult-to-express proteins 2020-05-19
Holmusk–SEVERAL: investment, 202005 financing round Series A $21.5m co-led by Optum Ventures + Health Catalayst Capital 2020-05-18
Oribiotech–CellGenix: reagents, 202005– collab supply of GMP raw materials for closed-system CGT manufacturing system of Ori 2020-05-13
Polyganics–Instinctif Partners: public relations, 202005 service existent by Instinctif 2020-05-13
Optibrium–OpenEye Scientific: cheminformatics, 202005– collab product integration OE libraries + toolkits with StarDrop software 2020-05-12
Compass Pathways–Able Partners: investment, 202004 financing round Series B totalling $80m incl new investor Able Partners 2020-04-27
Compass Pathways–ATAI Life Sciences: investment, 202004 financing round Series B totalling $80m incl existing investor ATAI Life Sciences 2020-04-27
Compass Pathways–Camden Partners: investment, 202004 financing round Series B totalling $80m incl new investor Camden Partners Nexus 2020-04-27
Compass Pathways–Founders Fund: investment, 202004 financing round Series B totalling $80m incl new investor Founders Fund 2020-04-27
Compass Pathways–Otsuka: investment, 202004 financing round Series B totalling $80m incl new investor MSRD 2020-04-27
Compass Pathways–Perceptive Advisors: investment, 202004 financing round Series B totalling $80m incl new investor Perceptive Advisors 2020-04-27
Compass Pathways–SEVERAL: investment, 202004 financing round Series B $80m from existing + new investors 2020-04-27
Compass Pathways–Skyviews Life Science: investment, 202004 financing round Series B totalling $80m incl new investor Skyviews Life Science 2020-04-27
Compass Pathways–Soleus Capital: investment, 202004 financing round Series B totalling $80m incl new investor Soleus Capital 2020-04-27
FoRx Therapeutics–Optimum Strategic Communications: public relations, 202004 service existent by Optimum 2020-04-22
Nanna Therapeutics–Astellas: investment, 202004 acquisition 100% for £12m upfront + £57.5m milestones by Astellas Pharma Europe Ltd 2020-04-21
MicrofluidX–88 Capital: investment, 202004 seed financing round totalling £1.4m incl angel contributions from 88 Capital 2020-04-20
MicrofluidX–Cambridge Angels: investment, 202004 seed financing round totalling £1.4m incl angel contributions from Cambridge Angels 2020-04-20
MicrofluidX–Longwall Ventures: investment, 202004 seed financing round totalling £1.4m incl investor Longwall Ventures 2020-04-20
MicrofluidX–Midven: investment, 202004 seed financing round totalling £1.4m incl investor UKI2S 2020-04-20
MicrofluidX–Moulton Goodies: investment, 202004 seed financing round totalling £1.4m incl investor Moulton Goodies Ltd 2020-04-20
MicrofluidX–SEVERAL: investment, 202004 seed financing round £1.4m from UKI2S + Longwall Ventures + Moulton Goodies + angel investors 2020-04-20
Avectas–PERSON: investment, 202004 financing round Series C totalling $20m incl existing + co-lead investor Seamus Mulligan 2020-04-16
Avectas–SEVERAL: investment, 202004 financing round Series C $20m led by exisiting shareholders incl Seamus Mulligan 2020-04-16
Evox Therapeutics–Cevec: cell line technology, 202004– license €na for use of CAP technology to produce exosome therapeutics as part of ongoing collab 2020-04-16
Cerevance–Lightstone Ventures: investment, 202004 financing round Series B totalling $45m incl existing investor Lightstone Ventures 2020-04-14
Cerevance–SEVERAL: investment, 202004 financing round Series B $45m with new investors GV + Bill Gates + Foresite Capital plus existing investors 2020-04-14
Cerevance–United Kingdom (govt): investment, 202004 financing round Series B totalling $45m incl existing investor Dementia Discovery Fund 2020-04-14
Amphista Therapeutics–Advent Venture Partners: investment, 202004 financing round Series A totalling $7.5m incl lead investor Advent Life Sciences 2020-04-07
Amphista Therapeutics–BioMotiv: investment, 202004 financing round Series A totalling $7.5m incl new + co-investor BioMotiv 2020-04-07
Amphista Therapeutics–EU (govt): investment, 202004 financing round Series A totalling $7.5m incl existing seed + co-investor European Investment Fund 2020-04-07
Amphista Therapeutics–Scius Communications: public relations, 202004 supply service existent by Scius Communications 2020-04-07
Amphista Therapeutics–Scotland (govt): investment, 202004 financing round Series A totalling $7.5m incl existing seed + co-investor SIB 2020-04-07
Amphista Therapeutics–SEVERAL: investment, 202004 financing round Series A $7.5m led by Advent Life Sciences + incl SIB + EIF + BioMotiv 2020-04-07
Gadeta–Optimum Strategic Communications: public relations, 202004 service existent by Optimum 2020-04-07
GSK–Vir Biotechnology: virostatic agents, 202004– collab r+d antiviral MAbs incl VIR-7831 + VIR-7832 targeting SARS-CoV-2 2020-04-06
Vir Biotechnology–GSK: investment, 202004 equity investment $250m at $37.73/share (10% premium to share price 27 Mar 2020) in connection with collab 2020-04-06
Axxam–ERS Genomics: CRISPR technology, 202004– license ww €na for drug discovery services of Axxam 2020-04-02
Evox Therapeutics–FTI Consulting: public relations, 202003 service existent by FTI Consulting 2020-03-26
SutroVax–Abingworth: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Abingworth 2020-03-26
SutroVax–Medicxi: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Medicxi 2020-03-26
SutroVax–SEVERAL: investment, 202003 financing round Series D $110m co-led by new investors RA Capital + Janus Henderson 2020-03-26
Takeda–Evox Therapeutics: exosome therapeutics, 202003– collab up to $926m + tiered royalties developm for up to 5 rare disease targets 2020-03-26
AstraZeneca–Silence Therapeutics: siRNA molecules, 202003– collab r+d strategic alliance $60m upfront + up to $400m for each disease target 2020-03-25
Silence Therapeutics–AstraZeneca: investment, 202003 equity investment $20m in connection with strategic siRNA alliance 2020-03-25
BMS–Oxford BioMedica: lentiviral vector technology, 202003– license non-excl + supply agreem LentiVector for CAR-T + TCR-T therapeutics of Juno 2020-03-18
Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS 2020-03-10
Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF 2020-03-10
Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical 2020-03-10
Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF 2020-03-10
Bone Therapeutics–Image Box: public relations, 202003– supply service by Image Box PR 2020-03-06
Autolus–MolMed: viral vectors, 202003– collab multi-year developm + supply of viral vectors by MolMed for T cell cancer therapies 2020-03-05
AstraZeneca–Voluntis: digital therapeutics, 202003 collab existent 2020-03-04
Next Gen Diagnostics–Fluidigm: nucleic acid sample preparation, 202003– collab excl Juno system for pathogen WGS sample preparation 2020-03-03
Evonetix–SEVERAL: investment, 202003 financing round Series B $30m (£23m) led by new investor Foresite Capital 2020-03-02
Immunocore–General Atlantic: investment, 202003 financing round Series B totalling $130m incl new + lead investor General Atlantic 2020-03-02
Immunocore–SEVERAL: investment, 202003 financing round Series B $130m led by new investor General Atlantic 2020-03-02
Sterling Pharma Solutions–Thermo Fisher: LC system, 202003 supply early customer for Vanquish Core HPLC System 2020-03-02
FinnGen–AstraZeneca: genomics, 202002 collab existent AstraZeneca is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–GSK: genomics, 202002 collab existent GSK is industry partner of Finnish genome research project FinnGen 2020-02-25
Roche–Bicycle Therapeutics: small-molecule drugs, 202002– collab strategic $30m upfront + up to $1.7b r+d of bicycle peptides for cancer Genentech 2020-02-25
GSK–Immatics: cell therapy, 202002– strategic collab $45m upfront + $1.1b milestones for first two TCR therapeutics programmes + royalties 2020-02-20
OMass–SEVERAL: investment, 202002 financing round Series A extension £27.5m bringing total Series A to £41.5m 2020-02-17
Pheno Therapeutics–SEVERAL: investment, 202002– financing round Series A £5m milestone-based over 3 years from Advent Life Sciences + SIB + LifeArc 2020-02-17
Pencil Biosciences–o2h: investment, 202002 investment by o2h Ventures Therapeutics and AI Fund 2020-02-15
Pencil Biosciences–United Kingdom (govt): grant, <202002 received Innovate UK grants 2020-02-15
Domainex–Sciad Communications: public relations, 202002 service existent by Sciad 2020-02-13
Inato–SEVERAL: investment, 202002 financing round Series A $14m led by Obious Ventures + Cathay Innovation 2020-02-04
Sumitomo–Exscientia: drug discovery, 202001 collab existent AI-based drug discovery using Centaur Chemist with Sumitomo Dainippon Pharma 2020-01-30
Stilla Technologies–Coulter Partners: recruitment services, 202001 supply service placement of Khaled Bahi as CFO at Stilla Technolgies 2020-01-28
Quench Bio–SEVERAL: investment, 202001 financing round Series A $50m led by RA Capital + incl AbbVie Ventures + Atlas Venture + Arix Bioscience 2020-01-27
iOnctura–SEVERAL: investment, 202001 financing round Series A €15m led by Inkef Capital + co-led by VI Partners 2020-01-23
Nanoform–Coulter Partners: recruitment services, 202001 supply service placement of Sally Langa as new head of US Sales at Nanoform 2020-01-21
Seekyo–Andrew Lloyd Associates: public relations, 202001 service existent by ALA 2020-01-20
Charles River–Fios Genomics: bioinformatics, 202001– collab providing Charles River’s customers access to Fios data analysis services 2020-01-16
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30  next pagenext page



Advertisement

Picture [iito] Männer Ballett 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top